Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Ludwig Oxford’s Dr Romuald Binet will investigate tissue-specific regulation of the DNA damage response in melanoma.

The DNA in our cells is damaged by natural biological processes and environmental factors every day. Fortunately, the body has effective DNA damage repair machinery that repairs the vast majority of this damage. The most common DNA damage – double-strand breaks – are recognised by the MRE11-RAD50-NSB1 (MRN) protein complex, which binds to the broken DNA and starts the recruitment of other repair factors.

DNA damage repair is an important consideration when selecting cancer therapies. Several treatments, including radiotherapy and some chemotherapies, work by damaging the cancer cell DNA, resulting in cancer cell death. Tumour types that are resistant to these types of treatment may have evolved specific DNA damage repair pathways. Learning more about these pathways may uncover new opportunities for therapeutic targeting.

Ludwig Oxford’s Dr Romuald Binet from Professor Colin Goding’s laboratory has been awarded a Development Fund from the Cancer Research UK Oxford Centre. Working with Professor Kristijan Ramadan (Department of Oncology) and Professor Davide Mazza (IRCCS Ospedale San Raffaele, Milan), Romuald will investigate DNA damage repair in cutaneous melanoma, a radioresistant skin cancer with high levels of DNA damage.

The team have already discovered that, in melanoma, the DNA damage response is modulated by a lineage-specific mechanism that alters the activity of the MRN complex. This project will precisely detail the mechanisms behind the deregulation of the MRN complex in melanoma to provide tissue-specific regulation of the DNA damage response.

Similar stories

Funded DPhil studentships available - apply now for October 2023 entry

Ludwig Oxford research groups are recruiting DPhil candidates for the funded DPhil in Cancer Science, NDM prize studentship and Oxford-MRC Doctoral Training Partnership Industrial Case programmes commencing in October 2023

Delving into MITF’s regulatory network in melanoma

Research from Ludwig Oxford’s Colin Goding and Department of Oncology’s Francesca Buffa uncovers new genes regulated by MITF in the context of the melanoma tumour microenvironment.